Cancer ResearchResearch PaperPaywall

First WRN Helicase Inhibitor Shows Promising Results in MSI Solid Tumors

A first-in-human phase 1 trial of RO7589831, a covalent WRN helicase inhibitor, demonstrates manageable safety and early antitumor activity in MSI cancers.

Thursday, October 1, 2026 0 views
Published in Nat Med
A researcher in a white lab coat examining a molecular model of a DNA helix on a computer screen in a modern oncology research laboratory

Summary

Some cancers have a broken DNA repair system called mismatch repair, which makes them genetically unstable. These tumors depend on an enzyme called WRN to survive. Researchers tested RO7589831, a pill that permanently blocks WRN, in 88 people with advanced cancers of this type. Nearly all had already tried immunotherapy and a median of three prior treatments. Side effects were mostly mild to moderate, mainly nausea, diarrhea, fatigue and anemia, and no treatment-related deaths occurred. Among 66 patients whose tumors could be evaluated, 74% had disease control, and 10.6% had tumors shrink substantially. Median time before progression was 6.7 months. Blood tests for tumor DNA and PET scans supported that the drug was working. This is an early, single-arm study, so larger trials are needed.

Detailed Summary

Microsatellite instability (MSI) tumors arise from defective DNA mismatch repair. They occur in about 4-7% of advanced colorectal cancers and 15-25% of advanced endometrial cancers. Immune checkpoint inhibitors have transformed care, but some patients never respond and others progress after initial benefit, leaving few good later-line options. Werner syndrome helicase (WRN) is a synthetic lethal vulnerability in these tumors, which depend on it to resolve unusual DNA structures and prevent replication fork collapse. RO7589831 (VVD-133214) is a first-in-class oral inhibitor that irreversibly binds WRN at cysteine 727.

Part 1 of this open-label, first-in-human phase 1 trial (NCT06004245) enrolled 88 patients at 17 centers in eight countries. Median age was 60, 56.8% were male, 64.8% had colorectal cancer, 9.1% endometrial cancer, and the rest other tumor types. Patients had a median of three prior therapy lines, and 95.5% had received a checkpoint inhibitor. Doses ranged from 150 mg once daily to 1,000 mg twice daily (BID), plus three-times-daily (TID) schedules, in 21-day cycles. Patients were then randomized 1:1:1 into backfill cohorts. Efficacy analyses covered 66 MSI-confirmed, evaluable patients.

Safety was manageable. Treatment-emergent events occurred in 98.9% of patients, grade 3-4 events in 46.6%, and serious events in 33.0%. No grade 5 events occurred, and 3.4% discontinued because of adverse events. The most common events were nausea (54.5%), diarrhea (43.2%), fatigue (39.8%), anemia (37.5%, with 11.4% grade 3+) and vomiting (30.7%). One dose-limiting toxicity (grade 2 nausea) occurred at 600 mg TID, and a maximum tolerated dose was not identified. Higher peak concentration predicted grade 2+ gastrointestinal toxicity (P=0.0002). Half-life was short, about 4.6 hours.

Disease control was 74.2% (49/66). Seven patients (10.6%) had confirmed partial responses, and 63.6% had stable disease. Median response duration was 10.2+ months, with five of seven responses ongoing. Median progression-free survival was 6.7 months overall and 7.3 months in colorectal cancer, and median overall survival was 17.6 months. Colorectal disease control was 80.5%, and three of six endometrial patients responded. No responses occurred in seven patients with microsatellite-stable tumors. Outcomes were similar regardless of prior checkpoint inhibitor response (72.7% vs 75.0% disease control).

Exploratory biomarkers supported biological activity. FDG-PET showed reduced tumor metabolism in 81.1% of evaluable patients, and metabolic response was associated with longer progression-free survival (HR 0.16, 95% CI 0.07-0.38). A 75% or greater ctDNA drop by cycle 2 strongly tracked disease control (OR 108.3, 95% CI 14.7-2,386.9), though the interval is very wide. Direct target engagement in tumor biopsies could not be shown, because only 5 of 26 biopsy pairs had enough tumor cells, likely due to mucinous histology.

The 150 mg and 600 mg BID doses were chosen for dose optimization, and TID schedules were dropped for tolerability and pill burden without better efficacy. Part 2 will test the drug with bevacizumab in colorectal cancer. Caveats include the single-arm design, small subgroups, heterogeneous tumors, no patient-reported outcomes, and a flat dose-response relationship. Several authors are employed by Roche or Vividion.

Key Findings

  • Disease control rate was 74.2% (49/66) in MSI efficacy-evaluable patients; across all 88 enrolled patients, 95.5% had received prior checkpoint inhibitor therapy
  • Objective response rate was 10.6% (7/66), with median duration of response 10.2+ months and 5 of 7 responses ongoing at cutoff
  • Median PFS was 6.7 months (95% CI 4.1-8.5) and median OS was 17.6 months; colorectal subgroup PFS was 7.3 months with 80.5% disease control
  • Grade 3-4 treatment-related adverse events occurred in 15.9%, discontinuations for adverse events in 3.4%, no grade 5 events; only one DLT (grade 2 nausea) and no MTD identified
  • Higher first-dose Cmax predicted grade 2+ gastrointestinal toxicity (P=0.0002), and 1,000 mg BID caused dose reductions in 6 of 11 patients
  • A 75% or greater ctDNA reduction by cycle 2 tracked disease control (OR 108.3, 95% CI 14.7-2,386.9, P=0.0001); 12 of 13 patients with progression lacked this response
  • FDG-PET metabolic response (CMR/PMR) was associated with longer PFS (HR 0.16, 95% CI 0.07-0.38); no responses occurred in 7 MSS patients

Methodology

This was an open-label, multicenter, first-in-human phase 1 trial across 17 centers in eight countries, enrolling 88 patients with MSI and/or dMMR advanced solid tumors from January 2024 to June 2025. Escalation used a modified continual reassessment method with overdose control, followed by 1:1:1 randomized backfill cohorts (150 mg QD, 200 mg TID, 600 mg TID). Primary endpoints were safety, MTD and RP2D; secondary endpoints included RECIST v1.1 response, DCR, DOR, PFS and OS, with exploratory pharmacokinetic, ctDNA, FDG-PET and tissue biomarker analyses. Efficacy was assessed in 66 MSI-confirmed evaluable patients, and the data cutoff was September 2025.

Study Limitations

The trial was single-arm and early phase, with small tumor-type subgroups, a heterogeneous heavily pretreated population, and no formal exposure-response relationship, so efficacy cannot be compared with standard care. Direct WRN target engagement could not be shown because biopsies had too few tumor cells and mucin interfered with the assay, and patient-reported outcomes were not collected. Biomarker analyses were exploratory and underpowered, with a very wide confidence interval for the ctDNA association, and Roche and Vividion employees are among the authors, indicating industry sponsorship.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: